FR20C1036I1 - PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Google Patents

PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Info

Publication number
FR20C1036I1
FR20C1036I1 FR20C1036C FR20C1036I1 FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1 FR 20C1036 C FR20C1036 C FR 20C1036C FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1
Authority
FR
France
Prior art keywords
precursor cells
mesenchymal precursor
perivascular mesenchymal
perivascular
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast Inc
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31500707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR20C1036I1 publication Critical patent/FR20C1036I1/en
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of FR20C1036I2 publication Critical patent/FR20C1036I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1392—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR20C1036C 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS Active FR20C1036I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003901668A AU2003901668A0 (en) 2003-03-28 2003-03-28 Non-haemopoietic precursor cells
EP04723935A EP1613741A4 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells
PCT/AU2004/000416 WO2004085630A1 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells

Publications (2)

Publication Number Publication Date
FR20C1036I1 true FR20C1036I1 (en) 2020-02-10
FR20C1036I2 FR20C1036I2 (en) 2022-11-18

Family

ID=31500707

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1036C Active FR20C1036I2 (en) 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Country Status (14)

Country Link
US (6) US7947266B2 (en)
EP (4) EP2380971B1 (en)
JP (10) JP2006521096A (en)
CN (4) CN103224907B (en)
AU (7) AU2003901668A0 (en)
CA (4) CA2872395A1 (en)
DK (1) DK1613335T3 (en)
ES (3) ES2465226T3 (en)
FR (1) FR20C1036I2 (en)
NL (1) NL301059I2 (en)
PL (1) PL1613335T3 (en)
PT (1) PT1613335E (en)
SI (1) SI1613335T1 (en)
WO (2) WO2004084921A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2515469C (en) * 2003-02-11 2013-12-17 John E. Davies Progenitor cells from wharton's jelly of human umbilical cord
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
TR201900968T4 (en) * 2004-09-24 2019-02-21 Mesoblast Inc Multipotential expanded mesenchymal precursor cell line (memp) and their use.
US8287853B2 (en) 2005-02-11 2012-10-16 Agency For Science, Technology And Research Methods of culturing mesenchymal stem cells
DE602006016735D1 (en) 2005-02-11 2010-10-21 Agency Science Tech & Res PROCESS FOR PROLIFERATION OF STEM CELLS
CA2604493C (en) 2005-04-12 2015-12-22 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP1909581A4 (en) * 2005-07-29 2008-12-31 Univ Virginia Adipose tissue stem cells, perivascular cells and pericytes
EP1780265A1 (en) * 2005-10-25 2007-05-02 Stiftung CAESAR Differentiation of stem cells into chondrocytes
AU2006329195B2 (en) * 2005-12-22 2012-09-20 John E. Davies Viable cells from frozen umbilical cord tissue
AU2007247725B2 (en) 2006-05-05 2013-02-14 Dolores Baksh Immune privileged and modulatory progenitor cells
JP6041456B2 (en) * 2006-07-12 2016-12-07 メゾブラスト，インコーポレーテッド Treatment of excessive neovascularization
FR2909559B1 (en) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang CELLULAR PREPARATIONS FOR USE AS AGENT STIMULATING REVASCULARIZATION
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
CA2679178A1 (en) * 2007-02-26 2008-09-04 Mount Sinai Hospital Compositions and methods for treating peripheral vascular diseases
TWI603736B (en) 2007-08-06 2017-11-01 安吉歐公司 Method for generating, repairing and/or maintaining connective tissue in vivo
JP5773366B2 (en) 2008-04-21 2015-09-02 ティシュー リジェネレイション セラピューティックス、インコーポレイテッド Human umbilical cord perivascular cells genetically modified for prevention or treatment of biological or chemical agents
TR201815802T4 (en) * 2008-06-25 2018-11-21 Mesoblast Inc Repair and / or reconstruction of invertabral discs.
AU2009269149B2 (en) * 2008-06-30 2016-03-17 Mesoblast, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010011185A1 (en) * 2008-07-21 2010-01-28 Agency For Science, Technology And Research Stem cells obtained through in vitro culture with heparan sulfate
EP3539380A3 (en) 2008-08-20 2019-12-18 Celularity, Inc. Improved cell composition and methods of making the same
MX2008014536A (en) * 2008-11-13 2009-01-16 Internac Para La Terapia Celul Cellular regenerator compound.
CN104546912B (en) * 2008-11-20 2019-11-08 中胚有限公司 Method for treating pancreas dysfunction
JP6342115B2 (en) * 2009-03-20 2018-06-13 メゾブラスト，インコーポレーテッド Generation of reprogrammed pluripotent cells
WO2011022070A2 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of California Perivascular stem cell composition for bone
WO2011048168A1 (en) 2009-10-21 2011-04-28 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
EP3366298B1 (en) 2010-07-02 2020-08-19 Mesoblast, Inc. Treatment of graft versus host disease
AU2011291537B2 (en) * 2010-08-19 2016-06-02 The Regents Of The University Of California Compositions comprising perivascular stem cells and Nell-1 protein
CN101985052B (en) * 2010-08-31 2013-11-06 中国人民解放军第二军医大学 Skin substitute for automatically capturing endothelial progenitor cells and promoting vascularization and construction method thereof
WO2012040408A2 (en) * 2010-09-23 2012-03-29 Children's Medical Center Corporation Engineered vascular adipose tissue
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
WO2012155209A1 (en) * 2011-05-19 2012-11-22 Mesoblast, Inc Methods for treating obesity and/or metabolic syndrome
CN112891374A (en) 2011-06-03 2021-06-04 麦瑟布莱斯特公司 Method of treating the effects of stroke
JP6184942B2 (en) * 2011-06-03 2017-08-23 メゾブラスト，インコーポレーテッド Methods for treating or preventing neurological diseases
EP2717894B1 (en) 2011-06-07 2018-01-24 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
WO2013003899A1 (en) 2011-07-04 2013-01-10 Mesoblast, Inc Methods of treating or preventing rheumatic disease
EA029577B1 (en) 2011-07-06 2018-04-30 Селл Терапи Лимитед Progenitor cells of mesodermal lineage
WO2013011131A2 (en) * 2011-07-20 2013-01-24 Angewandte Biotechnologie Gmbh Pluripotent tendon and ligament perivascular cells
JP2014529406A (en) * 2011-08-29 2014-11-13 セーフガードセル テクノロジー インク． Isolation and therapeutic use of perivascular medicinal cells
JP5831059B2 (en) * 2011-09-07 2015-12-09 ソニー株式会社 Optical measuring apparatus, flow cytometer, and optical measuring method
US9177336B2 (en) * 2011-09-08 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatuses and methods for recommending a path through an information space
US9642878B2 (en) 2011-09-09 2017-05-09 Mesoblast, Inc. Methods for increasing osteoblastic function
CN102539736B (en) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 CD106-positive cells, and identification and preparation method and application thereof
US10071123B2 (en) * 2012-08-01 2018-09-11 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
ES2869701T3 (en) 2012-08-01 2021-10-25 United Therapeutics Corp Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
EP2931373B1 (en) * 2012-12-12 2019-08-21 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
ES2697573T3 (en) * 2013-01-09 2019-01-25 United Therapeutics Corp Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
MX2016001247A (en) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same.
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
CA2933620A1 (en) * 2013-12-13 2015-06-18 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
CA2944262C (en) 2014-04-07 2023-08-01 Mesoblast International Sarl Improved stem cell composition
WO2015157694A1 (en) 2014-04-11 2015-10-15 The Administrators Of The Tulane Educational Fund Cell-surface marker of early msc aging
SG11201609993YA (en) 2014-06-10 2016-12-29 Mesoblast Internat Sàrl Treatment of immune disorders
CA2954743C (en) * 2014-07-11 2022-03-15 Metcela Inc. Cardiac cell culture material
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
CN114224916A (en) 2014-12-23 2022-03-25 迈索布拉斯特国际有限公司 Methods for treating heart failure
EP3237606A1 (en) 2014-12-23 2017-11-01 Mesoblast International Sàrl Prevention of progressive heart failure
JP6885870B2 (en) 2015-03-04 2021-06-16 メゾブラスト・インターナショナル・エスアーエールエル Cell culture method for mesenchymal stem cells
KR102582602B1 (en) 2015-05-05 2023-09-25 메조블라스트 인터내셔널 에스에이알엘 efficacy test
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
CN109415696A (en) 2016-05-25 2019-03-01 泰尔茂比司特公司 Cell amplification
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN106119189B (en) * 2016-07-11 2020-04-10 山东亚大药业有限公司 Separation and purification method and kit for fetal nucleated red blood cells
CN110177559A (en) 2016-10-24 2019-08-27 联合治疗学有限公司 Treprostinil enhanced MSC immunological regulation performance
JP7105195B2 (en) 2016-11-15 2022-07-22 株式会社カネカ Cell population containing mesenchymal stem cells derived from fetal appendages, method for producing the same, and pharmaceutical composition
JP6618066B2 (en) * 2017-02-24 2019-12-11 株式会社メトセラ Injectable composition for treating heart disease containing fibroblasts, and method for producing therapeutic fibroblasts
EP3601521A2 (en) 2017-03-31 2020-02-05 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP4137562A1 (en) 2017-05-04 2023-02-22 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
JP7454379B2 (en) 2017-12-28 2024-03-22 株式会社カネカ Cell population containing adherent stem cells, method for producing the same, and pharmaceutical composition
AU2019370723A1 (en) 2018-10-31 2021-05-13 Mesoblast International Sarl Expansion of hematopoietic stem cells
CN109321522A (en) * 2018-11-20 2019-02-12 潍坊市康华生物技术有限公司 A method of preparing dental pulp stem cell
US20220143097A1 (en) 2019-01-02 2022-05-12 Mesoblast International Sárl Method for treating lower back pain
BR112021012923A2 (en) 2019-01-03 2021-09-14 Mesoblast International Sàrl METHOD TO IMPROVE VISUAL ACUITY
US20220160776A1 (en) 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
WO2020234450A1 (en) 2019-05-23 2020-11-26 Mesoblast International Sarl Functional recovery from cerebral infarction
CN113993527A (en) 2019-06-14 2022-01-28 株式会社钟化 Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same
CA3149478A1 (en) 2019-08-05 2021-02-11 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
EP4192940A1 (en) 2020-08-10 2023-06-14 Mesoblast International Sárl Cellular compositions and methods of treatment
WO2023238074A1 (en) 2022-06-08 2023-12-14 Mesoblast International Sarl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells
CN115184246B (en) * 2022-09-14 2023-07-04 天津昂赛细胞基因工程有限公司 Method for evaluating biological efficacy of mesenchymal stem cells by using CD155
WO2024121821A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same
WO2024121820A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Pre-licensed composition and cell culture methods
WO2024121818A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
IL107642A0 (en) 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5405722A (en) * 1993-12-22 1995-04-11 Rca Thomson Licensing Corp. Method for combined baking-out and sealing of an electrophotographically processed screen assembly for a cathode-ray tube
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5922597A (en) * 1995-11-14 1999-07-13 Regents Of The University Of Minnesota Ex vivo culture of stem cells
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
CA2294944A1 (en) 1997-07-03 1999-01-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DK1082410T3 (en) 1998-05-29 2007-11-26 Osiris Therapeutics Inc Human CD45 and / or fibroblast mesenchymal stem cells
DE69937888T2 (en) * 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Process for the preparation of mesenchymal stem cells
KR100968164B1 (en) * 1999-03-10 2010-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Adipose-derived stem cells and lattices
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US8062675B2 (en) * 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
WO2001007679A1 (en) 1999-07-26 2001-02-01 Chemetall Plc Metal surface treatment
EP2348104A1 (en) 1999-08-05 2011-07-27 Mcl Llc Multipotent adult stem cells and methods for isolation
US6645727B2 (en) 2000-05-26 2003-11-11 Stemcell Technologies Inc. Antibody compositions for preparing enriched mesenchymal progenitor preparations
AU7707801A (en) 2000-07-21 2002-02-05 Us Health Adult human dental pulp stem cells in vitro and in vivo
EP1491093B1 (en) 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
FR2827868A1 (en) 2001-07-30 2003-01-31 Bp Chem Int Ltd Continuous production of styrene polymers, e.g. high-impact polystyrene, involves bulk polymerisation followed by two-stage devolatilisation of the melt in a special system to remove unreacted monomer and oligomers
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003052365A (en) * 2001-08-20 2003-02-25 Japan Science & Technology Corp Separation of mesenchymal stem cell from mammalian animal and method for using the same
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP4061487B2 (en) * 2002-11-21 2008-03-19 始 大串 Transplant material for angiogenesis and method for producing the same
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
ATE511753T1 (en) * 2003-04-19 2011-06-15 Us Gov Health & Human Serv POSTNATAL STEM CELLS AND THEIR USES
TR201900968T4 (en) 2004-09-24 2019-02-21 Mesoblast Inc Multipotential expanded mesenchymal precursor cell line (memp) and their use.
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
GB0812683D0 (en) * 2008-07-11 2008-08-20 Chalabi Rifat A Multi-heat zone gasifier
US7942266B2 (en) * 2009-04-01 2011-05-17 Lincoln Global, Inc. Electrode packaging to reduce handling damage

Also Published As

Publication number Publication date
CA2520390A1 (en) 2004-10-07
CN1809632A (en) 2006-07-26
JP2019006814A (en) 2019-01-17
EP1613335B1 (en) 2014-02-12
JP2015110659A (en) 2015-06-18
EP2380969A3 (en) 2011-11-09
CA2872395A1 (en) 2004-10-07
EP2380969A2 (en) 2011-10-26
EP2380971B1 (en) 2020-02-12
CA2520273C (en) 2015-06-02
EP1613335A4 (en) 2007-07-04
ES2465226T3 (en) 2014-06-05
US7947266B2 (en) 2011-05-24
CA2816489A1 (en) 2004-10-07
CA2520390C (en) 2015-03-24
US20120082649A1 (en) 2012-04-05
WO2004085630A1 (en) 2004-10-07
JP6257559B2 (en) 2018-01-10
AU2009227897A1 (en) 2009-11-12
ES2784378T3 (en) 2020-09-24
JP2006521096A (en) 2006-09-21
US20150368614A1 (en) 2015-12-24
US20060193840A1 (en) 2006-08-31
EP2380969B1 (en) 2018-07-04
JP2011072315A (en) 2011-04-14
EP2380971A3 (en) 2012-01-25
EP2380971A2 (en) 2011-10-26
AU2004224830B2 (en) 2006-06-29
AU2006203627A1 (en) 2006-09-07
FR20C1036I2 (en) 2022-11-18
JP2017014285A (en) 2017-01-19
CN1822846B (en) 2013-03-20
SI1613335T1 (en) 2014-08-29
NL301059I2 (en) 2021-09-16
ES2689483T3 (en) 2018-11-14
US20070065938A1 (en) 2007-03-22
EP1613741A1 (en) 2006-01-11
JP5721302B2 (en) 2015-05-20
JP6096082B2 (en) 2017-03-15
AU2009227881B2 (en) 2011-08-25
US9175267B2 (en) 2015-11-03
DK1613335T3 (en) 2014-05-19
AU2003901668A0 (en) 2003-05-01
JP6188435B2 (en) 2017-08-30
CA2816489C (en) 2022-08-23
JP6043469B2 (en) 2016-12-14
PL1613335T3 (en) 2014-09-30
CN103224907A (en) 2013-07-31
CA2520273A1 (en) 2004-10-07
CN103202857A (en) 2013-07-17
AU2004223798B2 (en) 2006-06-15
EP1613741A4 (en) 2007-07-04
JP2013208130A (en) 2013-10-10
PT1613335E (en) 2014-05-19
JP2006521121A (en) 2006-09-21
EP1613335A1 (en) 2006-01-11
CN1822846A (en) 2006-08-23
AU2004224830A1 (en) 2004-10-07
CN1809632B (en) 2013-06-05
US9169466B2 (en) 2015-10-27
US10421946B2 (en) 2019-09-24
AU2009227897B2 (en) 2011-09-15
WO2004084921A1 (en) 2004-10-07
NL301059I1 (en) 2020-08-12
AU2009227881A1 (en) 2009-11-12
JP6096232B2 (en) 2017-03-15
CN103224907B (en) 2015-05-06
AU2006203628A1 (en) 2006-09-07
JP2013256515A (en) 2013-12-26
AU2004223798A1 (en) 2004-10-07
US20160317581A1 (en) 2016-11-03
US20170204373A9 (en) 2017-07-20
JP2015156874A (en) 2015-09-03
US20060286077A1 (en) 2006-12-21
JP2017148076A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
FR20C1036I2 (en) PERIVASCULAR MESENCHYMAL PRECURSOR CELLS
DE60336590D1 (en) FUEL CELL
DE602004024016D1 (en) Electroacoustic conversion
ATE511364T1 (en) TOOTHBRUSH
DE602005003581D1 (en) ELECTROLYSIS CELL
DE602005000791D1 (en) interconnector
DE502005004462D1 (en) power float
IS2736B (en) Makrólíðsamrunaefnasambönd with @ @ @ anti-inflammatory activity
DE602005023645D1 (en) fuel cell
DE602004020394D1 (en) fuel cell
DE602005026944D1 (en) FUEL CELL
DE602005022581D1 (en) FUEL CELL
DE602004025608D1 (en) FUEL CELL
DE602004023588D1 (en) FUEL CELL
DK1665439T3 (en) solid oxide fuel cell
DE602005004061D1 (en) fuel cell unit
DE602004030501D1 (en) fuel cell
DE602004028858D1 (en) fuel cell
DE502004008433D1 (en) CELL
EP1743936A4 (en) Mesenchymal stem cell precursor
DE602004012181D1 (en) Thermo-electrochemical conversion arrangement
DE602005010396D1 (en) FUEL CELL
DE602005017686D1 (en) fuel cell
DE602004014451D1 (en) fuel cell
FI20051310A (en) brush structure